The COPD pipeline

Nature Reviews Drug Discovery

Volumn 13, Issue 4, 2014, Pages 253-254

  Mushtaq, Yasser ^a  

^a GBI Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDOLAST; BATEFENTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; GSK 961081; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL PLUS TIOTROPIUM BROMIDE; PHOSPHODIESTERASE INHIBITOR; RPL 554; TD 4208; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; UNCLASSIFIED DRUG;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG CHOICE; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY;

ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; DRUG DESIGN; HUMANS; INFLAMMATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84898597405     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4254     Document Type: Short Survey

References (4)

1. Kardos, P. et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 144-149 (2007).
2. Maltais, F. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients (Abstract 5557). Eur. Respir. J. 36 (Suppl. 54), 1014s (2010).
3. Franciosi, L. G. et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from our four clinical trials. Lancet Respir. Med. 9, 714-727 (2013).
4. GBI Research. Chronic Obstructive Pulmonary Disease (COPD) Market to 2019. GBIHC299MR (2013).